Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA). The main questions it aims to answer are: * Do beta-blockers improve coronary blood flow in patients with ANOCA? * Do beta-blockers reduce coronary microvascular resistance in these patients? Researchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation. Participants will: * Receive a beta-blocker or a placebo * Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR \>0.80 and no diameter stenosis \>50%

• Normal, TIMI 3 flow at angiography

• Stable haemodynamics

Locations
Other Locations
Belgium
OLV Cardiovascular Center Aalst
RECRUITING
Aalst
Contact Information
Primary
Adriaan Wilgenhof, MD
adriaan.wilgenhof@azorg.be
+32 53 72 44 39
Backup
Thabo Mahendiran, MD
thabo.mahendiran@doctors.org.uk
Time Frame
Start Date: 2025-07-03
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 46
Treatments
Placebo_comparator: Placebo
IV 0.9% NaCl (5 ml)
Active_comparator: Beta-blocker
IV metoprolol (5 ml of 1 mg/ml solution for injection)
Related Therapeutic Areas
Sponsors
Leads: VZW Cardiovascular Research Center Aalst

This content was sourced from clinicaltrials.gov